Skip to main content
Erschienen in: Clinical Rheumatology 6/2023

13.02.2023 | Original Article

Elevated platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with polymyositis/dermatomyositis: a retrospective study

verfasst von: Meiqi Li, Suyan Yan, Rongrong Dong, Weizhen Xiang, Zhenzhen Ma, Qingrui Yang

Erschienen in: Clinical Rheumatology | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Objectives

This study aimed to examine the diagnostic and prognostic value of the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) in patients with polymyositis/dermatomyositis (PM/DM).

Method

Clinical data of 200 patients with PM/DM and 204 healthy controls were retrospectively reviewed. We examined whether the PLR and NLR were associated with PM/DM.

Results

The PLR and NLR were higher in patients with PM/DM than in controls (both P < 0.001). The PLR and NLR were higher in patients with DM than in those with PM (both P < 0.01). The PLR was higher in the anti-melanoma differentiation-associated protein-5 (anti-MDA5) + PM/DM group than in the anti-MDA5- PM/DM group (P = 0.002). The NLR in non-survivors was higher than that in survivors (P = 0.01). The NLR was positively correlated with the occurrence of interstitial lung disease (ILD). The PLR and NLR were independent predictors of PM/DM, as well as risk factors (both P < 0.001). Moreover, the NLR had a predictive value for PM/DM-ILD and was closely related to mortality (P = 0.033, P = 0.003, respectively).

Conclusions

Patients with PM/DM have a higher NLR and PLR than healthy controls, especially in those with anti-MDA5+. The PLR and NLR are independent risk factors for PM/DM and have some predictive value. The NLR is correlated with ILD and associated with an increased risk of mortality in patients with PM/DM. The NLR and PLR may be simple, economical, and accurate diagnostic and prognostic markers for patients with PM/DM.
Key points
• The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been studied in numerous inflammatory diseases as potential markers, but their clinical significance in polymyositis/dermatomyositis (PM/DM) remains unclear.
• We examined the changes in the NLR and PLR between patients with PM/DM and healthy controls, as well as their association with mortality, interstitial lung disease, and anti-melanoma differentiation-associated protein-5.
• Patients with PM/DM may benefit from using the NLR and PLR as simple, economical, and accurate diagnostic and prognostic markers.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
6.
Zurück zum Zitat Sato S, Hoshino K, Satoh T et al (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 60(7):2193–2200. https://doi.org/10.1002/art.24621CrossRefPubMed Sato S, Hoshino K, Satoh T et al (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 60(7):2193–2200. https://​doi.​org/​10.​1002/​art.​24621CrossRefPubMed
8.
Zurück zum Zitat Chen Z, Cao M, Plana MN et al (2013) Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken) 65(8):1316–1324. https://doi.org/10.1002/acr.21985CrossRefPubMed Chen Z, Cao M, Plana MN et al (2013) Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken) 65(8):1316–1324. https://​doi.​org/​10.​1002/​acr.​21985CrossRefPubMed
12.
Zurück zum Zitat Li L, Xia Y, Chen C et al (2015) Neutrophil-lymphocyte ratio in systemic lupus erythematosus disease: a retrospective study. Int J Clin Exp Med 8(7):11026–11031PubMedPubMedCentral Li L, Xia Y, Chen C et al (2015) Neutrophil-lymphocyte ratio in systemic lupus erythematosus disease: a retrospective study. Int J Clin Exp Med 8(7):11026–11031PubMedPubMedCentral
29.
Zurück zum Zitat Ohsugi Y (2007) Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull 30(11):2001–2006. https://doi.org/10.1248/bpb.30.2001CrossRefPubMed Ohsugi Y (2007) Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull 30(11):2001–2006. https://​doi.​org/​10.​1248/​bpb.​30.​2001CrossRefPubMed
30.
Zurück zum Zitat Imai T, Koike K, Kubo T et al (1991) Interleukin-6 supports human megakaryocytic proliferation and differentiation in vitro. Blood 78(8):1969–1974CrossRefPubMed Imai T, Koike K, Kubo T et al (1991) Interleukin-6 supports human megakaryocytic proliferation and differentiation in vitro. Blood 78(8):1969–1974CrossRefPubMed
37.
39.
Zurück zum Zitat Colotta F, Re F, Polentarutti N et al (1992) Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80(8):2012–2020CrossRefPubMed Colotta F, Re F, Polentarutti N et al (1992) Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80(8):2012–2020CrossRefPubMed
Metadaten
Titel
Elevated platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with polymyositis/dermatomyositis: a retrospective study
verfasst von
Meiqi Li
Suyan Yan
Rongrong Dong
Weizhen Xiang
Zhenzhen Ma
Qingrui Yang
Publikationsdatum
13.02.2023
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 6/2023
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-023-06542-7

Weitere Artikel der Ausgabe 6/2023

Clinical Rheumatology 6/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.